Report : Middle East and Africa Generic Injectables Market Forecast to 2028 - COVID-19 Impact and Regional Analysis By Product Type (Large Molecule Injectables and Small Molecule Injectables), Container Type (Vials, Premix, Prefilled Syringes, Ampoules, and Others), Application (Oncology, Infectious Diseases, Cardiology, Diabetes, Immunology, and Others), and Route of Administration (Intravenous, Intramuscular, Subcutaneous, and Others)
Intravenous Segment to Dominate Middle East & Africa Generic Injectables Market during 2019–2028
According to a new market research study on “Middle East & Africa Generic Injectables Market to 2028 – COVID-19 Impact and Regional Analysis and Forecast by Product Type, Container Type, Application, and Route of Administration,” is expected to reach US$ 6,616.77 million by 2028 from US$ 3,717.72 million in 2021. The market is estimated to grow at a CAGR of 8.6% from 2021 to 2028. Increasing patent expiry of drugs is the major factor driving the growth of the Middle East & Africa generic injectables market. However, critical inspection system for prefilled injection may hinder the growth of Middle East & Africa generic injectables market. The report provides trends prevailing in the Middle East & Africa generic injectables market along with the drivers and restraints pertaining to the market growth.
The Middle East & Africa generic injectables market is segmented into product type, container type, application, route of administration, and country. The Middle East & Africa generic injectables market, based on product type, has been segmented into large molecule injectable and small molecule injectable. In 2020, the large molecule injectable segment held the largest share Middle East & Africa generic injectables market. The Middle East & Africa generic injectables market, based on container type, has been categorized into vials, premix, prefilled syringes, ampoules, and others. In 2020, the vials segment held the largest share Middle East & Africa generic injectables market. The Middle East & Africa generic injectables market, based on application, has been categorized into oncology, infectious diseases, cardiology, diabetes, immunology, and others. In 2020, the oncology segment held the largest share Middle East & Africa generic injectables market. The Middle East & Africa generic injectables market, based on route of administration, has been categorized into intravenous, intramuscular, subcutaneous, and others. In 2020, the intravenous segment held the largest share Middle East & Africa generic injectables market. Similarly, based on country, the Middle East & Africa generic injectables market is segmented into Saudi Arabia, South Africa, the UAE, and the rest of Middle East & Africa. Saudi Arabia contributed a substantial share in 2020.
AstraZeneca; Baxter International Inc.; Biocon; Fresenius SE & Co. KGaA; GlaxoSmithKline plc; Hikma Pharmaceuticals PLC; Johnson and Johnson Services, Inc.; Lupin; Merck & Co., Inc.; Pfizer Inc.; and Viatris Inc are among the leading companies in the Middle East & Africa generic injectables market. The companies are focused on adopting organic growth strategies such as product launches and expansions to sustain their position in the dynamic market. For instance, in 2021, Hikma Pharmaceuticals PLC announced that it has agreed to acquire Custopharm Inc. This strategy complements Hikma’s injectable product portfolio and pipeline, adding 13 approved products and additional pipeline products.
Contact Us
Contact Person: Sameer Joshi
Phone: +1-646-491-9876
Email Id: sales@businessmarketinsights.com